biotechnology

High-Beta Names Lead Stocks Lower – Briefing.com

[BRIEFING.COM] The major averages spent the last session of the week in a steady retreat despite receiving a round of better than expected earnings from the technology sector. The Nasdaq lost 1.8%, widening its April decline to 2.9%, while the S&P 500 fell 0.8%, swinging to a month-to-date loss to 0.5%. The benchmark index notched a session low not far […]

Stock Market Crash Signal 2014 20 Stocks All Short Plays Huge …

http://www.StockMarketFunding.com Stock Market Crash Signs 2014 20 Stocks All Short Plays Huge Shorts Massive Trading Profits (VIDEO). Learn how to make money shorting stocks through this live stock trading education video.We’ll cover PCLN, ICPT which traded with a $50 trading range closing down $34.88 or 11.64%. We’ll cover Google shares GOOG and GOOGL and options strategies.SMF will look at CSGP […]

Five Star Stock Watch: Gilead Sciences | Benzinga

One part of the market has held on, another part seems to be falling apart.
Over the last month or so the S&P 500 and Dow Jones Industrials have essentially moved sideways, but the Nasdaq and Russell 2000 have clearly trended lower.
Tech stocks, and specifically biotech stocks, have really taken a beating. However, there has been a slight recovery over the […]

Learn How to Profit Trading Biotech Stocks 2014 BIIB CELG REGN …

http://www.StockMarketFunding.com Learn How to Profit Trading Biotech Stocks 2014 (VIDEO). NASDAQ Biotechnology Index Commentary & Biotech Stock to Watch (VIDEO). We’ll cover detailed technical analysis trends on the Nasdaq Biotechnology Index which has been on fire lately!We’ll cover key technical analysis trends and how to trade shares of Biogen Idec (BIIB), REGN, CELG, Gilead Sciences (GILD), Intercept Pharmaceuticals, Inc. (ICPT), […]

Putting Biotech Stocks Under the Microscope – Barron's

In 1996, fresh out Harvard, Rajiv Kaul went to work as an analyst covering biotechnology at Fidelity Investments. At the time, the sector was still considered a risky niche—the perfect project for the new guy. “Biotech was viewed like a lottery ticket,” says Kaul, 41. “It was something conventional investors shied away from.”
Where others saw uncertainty, Kaul saw possibility. After […]